A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time-to-Event Outcomes Using Average Hazard with Survival Weight
Abstract: Given the limitations of using the Cox hazard ratio to summarize the magnitude of the treatment effect, alternative measures that do not have these limitations are gaining attention. One of the recently proposed alternative methods uses the average hazard with survival weight (AH). This population quantity can be interpreted as the average intensity of the event occurrence in a given time window that does not involve study-specific censoring. Inference procedures for the ratio of AH and difference in AH have already been proposed in simple randomized controlled trial settings to compare two groups. However, methods with stratification factors have not been well discussed, although stratified analysis is often used in practice to adjust for confounding factors and increase the power to detect a between-group difference. The conventional stratified analysis or meta-analysis approach, which integrates stratum-specific treatment effects using an optimal weight, directly applies to the ratio of AH and difference in AH. However, this conventional approach has significant limitations similar to the Cochran-Mantel-Haenszel method for a binary outcome and the stratified Cox procedure for a time-to-event outcome. To address this, we propose a new stratified analysis method for AH using standardization. With the proposed method, one can summarize the between-group treatment effect in both absolute difference and relative terms, adjusting for stratification factors. This can be a valuable alternative to the traditional stratified Cox procedure to estimate and report the magnitude of the treatment effect on time-to-event outcomes using hazard.
- CONSORT 2010 declaration: updated guideline for reporting parallel group randomised trials. Med. Clin. 137, 213–215.
- Counting Processes and Survival Analysis. John Wiley & Sons, New York.
- Enhanced secondary analysis of survival data: reconstructing the data from published kaplan-meier survival curves. BMC medical research methodology 12, 1–13.
- How do the accrual pattern and follow-up duration affect the hazard ratio estimate when the proportional hazards assumption is violated? Oncologist 24, 867–871.
- Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase iii arasens trial. Journal of Clinical Oncology 41, 3595–3607.
- Estimation of the average hazard ratio. Biometrika 68, 105–112.
- The Robust Inference for the Cox Proportional Hazards Model. J Am Stat Assoc 84, 1074–1078.
- Modern Epidemiology, 3rd Edition. Lippincott Williams & Wilkins, Philadelphia.
- Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. J Immunother Cancer 9,.
- Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study. Stat. Med. 38, 917–932.
- Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 32, 2380–2385.
- Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy. Stat. Med. 42, 936–952.
- Woolf, B. (1955). On estimating the relation between blood group and disease. Ann. Hum. Genet. 19, 251–253.
- Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials 9, 570–577.
Paper Prompts
Sign up for free to create and run prompts on this paper using GPT-5.
Top Community Prompts
Collections
Sign up for free to add this paper to one or more collections.